STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Creators
- 1. Department of General, Visceral and Pediatric Surgery, University Medicine Göttingen, Robert-Koch-Str. 40, Göttingen 37075 (Germany)
- 2. Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 (United States)
- 3. Department of Radiotherapy and Radiooncology, University Medicine Göttingen, Robert-Koch-Str. 40, Göttingen 37075 (Germany)
- 4. Department of Cellular and Molecular Immunology, University Medicine Göttingen, Humboldtallee 34, Göttingen 37073 (Germany)
Description
Chemoradiotherapy (CRT) represents a standard treatment for many human cancers, frequently combined with radical surgical resection. However, a considerable percentage of primary cancers are at least partially resistant to CRT, which represents a substantial clinical problem, because it exposes cancer patients to the potential side effects of both irradiation and chemotherapy. It is therefore exceedingly important to determine the molecular characteristics underlying CRT-resistance and to identify novel molecular targets that can be manipulated to re-sensitize resistant tumors to CRT. In this review, we highlight much of the recent evidence suggesting that the signal transducer and activator of transcription 3 (STAT3) plays a prominent role in mediating CRT-resistance, and we outline why inhibition of STAT3 holds great promise for future multimodal treatment concepts in oncology
Availability note (English)
Available from http://dx.doi.org/10.3390/cancers6041986; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276953Additional details
Identifiers
Publishing Information
- Journal Title
- Cancers (Basel)
- Journal Volume
- 6
- Journal Issue
- 4
- Journal Page Range
- p. 1986-2011
- ISSN
- 2072-6694
INIS
- Country of Publication
- Switzerland
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47006783
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- COMBINED THERAPY; NEOPLASMS; RADIOTHERAPY; SIDE EFFECTS
- Descriptors DEC
- DISEASES; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2014 by the authors
- Notes
- PMCID: PMC4276953; PMID: 25268165; PUBLISHER-ID: cancers-06-01986; OAI: oai:pubmedcentral.nih.gov:4276953; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).